.
Gametas e embriões
desperdiçados A(gosto)
𝖠̀ 𝗌𝖾𝗆𝖾𝗅𝗁𝖺𝗇𝖼̧𝖺 𝖽𝖺 𝖾𝗌𝗆𝖺𝗀𝖺𝖽𝗈𝗋𝖺 𝗆𝖺𝗂𝗈𝗋𝗂𝖺 𝖽𝗈𝗌 𝗉𝖺𝗂́𝗌𝖾𝗌 𝖽𝖾𝗌𝖾𝗇𝗏𝗈𝗅𝗏𝗂𝖽𝗈𝗌, 𝖯𝗈𝗋𝗍𝗎𝗀𝖺𝗅 𝖾𝗌𝗍𝖺́ 𝖾𝗇𝗏𝖾𝗅𝗁𝖾𝖼𝗂𝖽𝗈. 𝖠 𝗋𝖾𝗇𝗈𝗏𝖺𝖼̧𝖺̃𝗈 𝖽𝖾 𝗀𝖾𝗋𝖺𝖼̧𝗈̃𝖾𝗌 𝖾𝗌𝗍𝖺́ 𝗆𝗎𝗂𝗍𝗈 𝗅𝗈𝗇𝗀𝖾 𝖽𝖾 𝖺𝗌𝗌𝖾𝗀𝗎𝗋𝖺𝖽𝖺, 𝖼𝗈𝗆 𝖺 𝗉𝗂𝗋𝖺̂𝗆𝗂𝖽𝖾 𝖾𝗍𝖺́𝗋𝗂𝖺 𝗂𝗇𝗏𝖾𝗋𝗍𝗂𝖽𝖺 𝗁𝖺́ 𝖽𝖾́𝖼𝖺𝖽𝖺𝗌, 𝖾𝗑𝗂𝗌𝗍𝗂𝗇𝖽𝗈 𝖺𝖼𝗍𝗎𝖺𝗅𝗆𝖾𝗇𝗍𝖾 𝖻𝖾𝗆 𝗆𝖺𝗂𝗌 𝗂𝖽𝗈𝗌𝗈𝗌 𝖽𝗈 𝗊𝗎𝖾 𝗃𝗈𝗏𝖾𝗇𝗌.
𝖤𝗌𝗍𝖺 𝗉𝗋𝖾𝗏𝖺𝗅𝖾̂𝗇𝖼𝗂𝖺 𝖽𝖺 𝖿𝖺𝗂𝗑𝖺 𝖾𝗍𝖺́𝗋𝗂𝖺 𝗆𝖺𝗂𝗌 𝗏𝖾𝗅𝗁𝖺 𝗉𝗈𝖽𝖾𝗋𝖺́ 𝗌𝖾𝗋 𝗆𝗈𝗍𝗂𝗏𝖺𝖽𝖺 𝗉𝗈𝗋 𝖽𝗂𝖿𝖾𝗋𝖾𝗇𝗍𝖾𝗌 𝖿𝖺𝖼𝗍𝗈𝗋𝖾𝗌: 𝗈 𝖺𝗎𝗆𝖾𝗇𝗍𝗈 𝖽𝖺 𝖾𝗌𝗉𝖾𝗋𝖺𝗇𝖼̧𝖺 𝗆𝖾́𝖽𝗂𝖺 𝖽𝖾 𝗏𝗂𝖽𝖺; 𝗌𝗂𝗍𝗎𝖺𝖼̧𝗈̃𝖾𝗌 𝖾𝗆 𝗊𝗎𝖾 𝗈𝗌 𝖼𝖺𝗌𝖺𝗂𝗌, 𝗇𝖺 𝗌𝗎𝖺 𝗅𝗂𝖻𝖾𝗋𝖽𝖺𝖽𝖾, 𝗇𝖺̃𝗈 𝖽𝖾𝗌𝖾𝗃𝖺𝗆 𝗍𝖾𝗋 𝖿𝗂𝗅𝗁𝗈𝗌; 𝗈𝗎 𝖻𝖺𝗂𝗑𝖺𝗌 𝗍𝖺𝗑𝖺𝗌 𝖽𝖾 𝗇𝖺𝗍𝖺𝗅𝗂𝖽𝖺𝖽𝖾 𝖾𝗆 𝗏𝗂𝗋𝗍𝗎𝖽𝖾 𝖽𝖾 𝖼𝗂𝗋𝖼𝗎𝗇𝗌𝗍𝖺̂𝗇𝖼𝗂𝖺𝗌 𝖾𝖼𝗈𝗇𝗈́𝗆𝗂𝖼𝖺𝗌, 𝗅𝖺𝖻𝗈𝗋𝖺𝗂𝗌, 𝗌𝗈𝖼𝗂𝖺𝗂𝗌 𝖾 (𝗈 𝗆𝖺𝗂𝗈𝗋 𝗍𝖺𝖻𝗎 𝖽𝖾 𝗍𝗈𝖽𝗈𝗌) 𝖽𝖾 𝗌𝖺𝗎́𝖽𝖾.
𝖮𝗌 𝖽𝖺𝖽𝗈𝗌 𝗆𝗈𝗌𝗍𝗋𝖺𝗆 𝗊𝗎𝖾 𝖺 𝗂𝗇𝖿𝖾𝗋𝗍𝗂𝗅𝗂𝖽𝖺𝖽𝖾 𝗍𝖾𝗆 𝖺𝗎𝗆𝖾𝗇𝗍𝖺𝖽𝗈 𝖾𝗆 𝖯𝗈𝗋𝗍𝗎𝗀𝖺𝗅. 𝖤𝗌𝗍𝖺 𝗍𝖾𝗇𝖽𝖾̂𝗇𝖼𝗂𝖺 𝗇𝖺̃𝗈 𝗌𝖾𝗋𝖺́ 𝗇𝖾𝖼𝖾𝗌𝗌𝖺𝗋𝗂𝖺𝗆𝖾𝗇𝗍𝖾 𝖼𝗈𝗇𝗌𝖾𝗊𝗎𝖾̂𝗇𝖼𝗂𝖺 𝖽𝖾 𝗉𝖺𝗍𝗈𝗅𝗈𝗀𝗂𝖺𝗌 𝖼𝗅𝗂́𝗇𝗂𝖼𝖺𝗌 𝗆𝖺𝗂𝗌 𝗈𝗎 𝗆𝖾𝗇𝗈𝗌 𝖼𝗈𝗇𝗁𝖾𝖼𝗂𝖽𝖺𝗌 𝖽𝗈 𝖼𝖺𝗌𝖺𝗅 𝖺𝗊𝗎𝖺𝗇𝖽𝗈 𝖽𝗈 𝗉𝗅𝖺𝗇𝖾𝖺𝗆𝖾𝗇𝗍𝗈 𝖽𝖺 𝖼𝗈𝗇𝖼𝖾𝗉𝖼̧𝖺̃𝗈, 𝗆𝖺𝗌 𝗌𝗂𝗆, 𝗉𝖾𝗅𝗈 𝖿𝖺𝖼𝗍𝗈 𝖽𝖾 𝗈𝗌 𝖼𝖺𝗌𝖺𝗂𝗌 𝗍𝖾𝗋𝖾𝗆 𝖿𝗂𝗅𝗁𝗈𝗌 𝖼𝖺𝖽𝖺 𝗏𝖾𝗓 𝗆𝖺𝗂𝗌 𝗍𝖺𝗋𝖽𝖾. 𝖤𝗌𝗍𝖾 𝗋𝖾𝗍𝖺𝗋𝖽𝖺𝗋 𝖽𝗈 𝗉𝗋𝗈𝖼𝖾𝗌𝗌𝗈 𝗋𝖾𝗉𝗋𝗈𝖽𝗎𝗍𝗂𝗏𝗈 𝗍𝖾𝗆 𝗎𝗆 𝗂𝗆𝗉𝖺𝖼𝗍𝗈 𝖼𝗈𝗇𝗌𝗂𝖽𝖾𝗋𝖺́𝗏𝖾𝗅 𝗇𝖺 𝗊𝗎𝖺𝗅𝗂𝖽𝖺𝖽𝖾 𝖽𝗈𝗌 𝗀𝖺𝗆𝖾𝗍𝖺𝗌 (𝗈́𝗏𝗎𝗅𝗈𝗌 𝖾 𝖾𝗌𝗉𝖾𝗋𝗆𝖺𝗍𝗈𝗓𝗈𝗂𝖽𝖾𝗌), 𝖼𝗈𝗆 𝗆𝖺𝗂𝗈𝗋 𝗉𝗋𝖾𝗏𝖺𝗅𝖾̂𝗇𝖼𝗂𝖺 𝗇𝖺𝗌 𝗆𝗎𝗅𝗁𝖾𝗋𝖾𝗌, 𝖾𝗆 𝗉𝖺𝗋𝗍𝗂𝖼𝗎𝗅𝖺𝗋, 𝖺 𝗉𝖺𝗋𝗍𝗂𝗋 𝖽𝗈𝗌 𝟥𝟧 𝖺𝗇𝗈𝗌 𝖽𝖾 𝗂𝖽𝖺𝖽𝖾.
𝖥𝖾𝗅𝗂𝗓𝗆𝖾𝗇𝗍𝖾, 𝗈𝗌 𝖺𝗏𝖺𝗇𝖼̧𝗈𝗌 𝖼𝗂𝖾𝗇𝗍𝗂́𝖿𝗂𝖼𝗈𝗌 𝖾 𝗍𝖾𝖼𝗇𝗈𝗅𝗈́𝗀𝗂𝖼𝗈𝗌 𝗉𝖾𝗋𝗆𝗂𝗍𝗂𝗋𝖺𝗆 𝖺𝗉𝗋𝖾𝗌𝖾𝗇𝗍𝖺𝗋 𝗎𝗆𝖺 𝖺𝗅𝗍𝖾𝗋𝗇𝖺𝗍𝗂𝗏𝖺 𝖺𝗈𝗌 𝗊𝗎𝖾, 𝖽𝖾𝗌𝖾𝗃𝖺𝗇𝖽𝗈 𝗍𝖾𝗋 𝖿𝗂𝗅𝗁𝗈𝗌, 𝗌𝖾 𝖾𝗇𝖼𝗈𝗇𝗍𝗋𝖺𝗏𝖺𝗆 𝗂𝗆𝗉𝗈𝗌𝗌𝗂𝖻𝗂𝗅𝗂𝗍𝖺𝖽𝗈𝗌 𝖽𝖾 𝖼𝗈𝗇𝖼𝗋𝖾𝗍𝗂𝗓𝖺𝗋 𝖾𝗌𝗌𝖾 𝖽𝖾𝗌𝖾𝗃𝗈. 𝖠𝗉𝖾𝗌𝖺𝗋 𝖽𝗈𝗌 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈𝗌 𝖽𝖾 𝗉𝗋𝗈𝖼𝗋𝗂𝖺𝖼̧𝖺̃𝗈 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝖾 𝖺𝗌𝗌𝗂𝗌𝗍𝗂𝖽𝖺 𝗌𝖾𝗋𝖾𝗆 𝗎𝗆𝖺 𝗋𝖾𝖺𝗅𝗂𝖽𝖺𝖽𝖾 𝗁𝖺́ 𝗊𝗎𝖺𝗍𝗋𝗈 𝖽𝖾́𝖼𝖺𝖽𝖺𝗌, 𝗂𝗇𝖿𝖾𝗅𝗂𝗓𝗆𝖾𝗇𝗍𝖾, 𝖺 𝖼𝖺𝗉𝖺𝖼𝗂𝖽𝖺𝖽𝖾 𝖽𝗈 𝖲𝖾𝗋𝗏𝗂𝖼̧𝗈 𝖭𝖺𝖼𝗂𝗈𝗇𝖺𝗅 𝖽𝖾 𝖲𝖺𝗎́𝖽𝖾 (𝖲𝖭𝖲) 𝖾𝗆 𝖽𝖺𝗋 𝗋𝖾𝗌𝗉𝗈𝗌𝗍𝖺 𝖺𝗈𝗌 𝗉𝖺𝖼𝗂𝖾𝗇𝗍𝖾𝗌 𝗊𝗎𝖾 𝗉𝗋𝗈𝖼𝗎𝗋𝖺𝗆 𝗎𝗆𝖺 𝗌𝗈𝗅𝗎𝖼̧𝖺̃𝗈 𝗃𝗎𝗇𝗍𝗈 𝖽𝗈 𝗌𝖾𝖼𝗍𝗈𝗋 𝗉𝗎́𝖻𝗅𝗂𝖼𝗈 𝖽𝖾 𝗌𝖺𝗎́𝖽𝖾 𝖾𝗆 𝖯𝗈𝗋𝗍𝗎𝗀𝖺𝗅 𝖾𝗌𝗍𝖺́ 𝗅𝗈𝗇𝗀𝖾 𝖽𝖺 𝗂𝖽𝖾𝖺𝗅.
𝖯𝗈𝗋 𝗎𝗆 𝗅𝖺𝖽𝗈, 𝖺𝗍𝖾𝗇𝖽𝖾𝗇𝖽𝗈 𝖺̀ 𝖽𝗂𝗆𝗂𝗇𝗎𝗂𝖼̧𝖺̃𝗈 𝖽𝖺 𝗊𝗎𝖺𝗅𝗂𝖽𝖺𝖽𝖾 𝖽𝗈𝗌 𝗈́𝗏𝗎𝗅𝗈𝗌 𝖼𝗈𝗆 𝗈 𝗉𝖺𝗌𝗌𝖺𝗋 𝖽𝗈𝗌 𝖺𝗇𝗈𝗌, 𝖺 𝗂𝖽𝖺𝖽𝖾 𝗆𝖺́𝗑𝗂𝗆𝖺 𝖼𝗈𝗆 𝗊𝗎𝖾 𝗎𝗆𝖺 𝗆𝗎𝗅𝗁𝖾𝗋 𝗉𝗈𝖽𝖾 𝖺𝖼𝖾𝖽𝖾𝗋 𝖺𝗈𝗌 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈𝗌 𝗇𝗈 𝖲𝖭𝖲 𝖾𝗌𝗍𝖺́ 𝖿𝗂𝗑𝖺𝖽𝖺 𝗇𝗈𝗌 𝟦𝟢 𝖺𝗇𝗈𝗌 𝖽𝖾 𝗂𝖽𝖺𝖽𝖾.
𝖮𝗎𝗍𝗋𝖺 𝗋𝖺𝗓𝖺̃𝗈 𝖾𝗌𝗍𝖺́ 𝗋𝖾𝗅𝖺𝖼𝗂𝗈𝗇𝖺𝖽𝖺 𝖼𝗈𝗆 𝖺𝗌𝗌𝗂𝗆𝖾𝗍𝗋𝗂𝖺𝗌 𝗍𝖾𝗋𝗋𝗂𝗍𝗈𝗋𝗂𝖺𝗂𝗌 - 𝗈 𝖠𝗅𝖾𝗇𝗍𝖾𝗃𝗈, 𝗈 𝖠𝗅𝗀𝖺𝗋𝗏𝖾 𝖾 𝖺 𝖱𝖾𝗀𝗂𝖺̃𝗈 𝖠𝗎𝗍𝗈́𝗇𝗈𝗆𝖺 𝖽𝗈𝗌 𝖠𝖼̧𝗈𝗋𝖾𝗌 𝗇𝖺̃𝗈 𝗍𝖾̂𝗆 𝗊𝗎𝖺𝗅𝗊𝗎𝖾𝗋 𝖼𝖾𝗇𝗍𝗋𝗈 𝗉𝗎́𝖻𝗅𝗂𝖼𝗈 𝖽𝖾 𝗉𝗋𝗈𝖼𝗋𝗂𝖺𝖼̧𝖺̃𝗈 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝖾 𝖺𝗌𝗌𝗂𝗌𝗍𝗂𝖽𝖺. 𝖢𝗈𝗇𝗌𝖾𝗊𝗎𝖾𝗇𝗍𝖾𝗆𝖾𝗇𝗍𝖾, 𝗊𝗎𝖾𝗆 𝗉𝗋𝖾𝗍𝖾𝗇𝖽𝖺 𝗉𝗋𝗈𝖼𝗋𝗂𝖺𝗋 𝗎𝗍𝗂𝗅𝗂𝗓𝖺𝗇𝖽𝗈 𝗎𝗆 𝗆𝖾́𝗍𝗈𝖽𝗈 𝖺𝗅𝗍𝖾𝗋𝗇𝖺𝗍𝗂𝗏𝗈 𝗍𝖾𝗋𝖺́ 𝖽𝖾 𝖽𝖾𝗌𝗅𝗈𝖼𝖺𝗋-𝗌𝖾 𝖼𝖾𝗇𝗍𝖾𝗇𝖺𝗌 𝖽𝖾 𝗊𝗎𝗂𝗅𝗈́𝗆𝖾𝗍𝗋𝗈𝗌 𝗉𝖺𝗋𝖺 𝖺𝖼𝖾𝖽𝖾𝗋 𝖺 𝗎𝗆 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈 𝖽𝖾𝗆𝗈𝗋𝖺𝖽𝗈 𝖾 𝗌𝖾𝗆 𝖼𝖾𝗋𝗍𝖾𝗓𝖺𝗌 𝗊𝗎𝖺𝗇𝗍𝗈 𝖺𝗈 𝗌𝖾𝗎 𝗌𝗎𝖼𝖾𝗌𝗌𝗈.
𝖯𝗈𝗋 𝗎́𝗅𝗍𝗂𝗆𝗈, 𝖾 𝗇𝖺̃𝗈 𝗋𝖺𝗋𝖺𝗌 𝗏𝖾𝗓𝖾𝗌 𝖽𝖾𝖼𝗂𝗌𝗂𝗏𝗈, 𝗈𝗌 𝗍𝖾𝗆𝗉𝗈𝗌 𝖽𝖾 𝖾𝗌𝗉𝖾𝗋𝖺. 𝖠𝖼𝗍𝗎𝖺𝗅𝗆𝖾𝗇𝗍𝖾, 𝗊𝗎𝖾𝗋 𝗉𝖺𝗋𝖺 𝗈𝗌 𝗀𝖺𝗆𝖾𝗍𝖺𝗌 𝗆𝖺𝗌𝖼𝗎𝗅𝗂𝗇𝗈𝗌, 𝖼𝗈𝗆𝗈 𝗉𝖺𝗋𝖺 𝗈𝗌 𝖿𝖾𝗆𝗂𝗇𝗂𝗇𝗈𝗌, 𝗈 𝗍𝖾𝗆𝗉𝗈 𝖽𝖾 𝖾𝗌𝗉𝖾𝗋𝖺 𝖺𝗍𝗂𝗇𝗀𝖾 𝗈𝗌 𝗍𝗋𝖾̂𝗌 𝖺𝗇𝗈𝗌 𝖾 𝗆𝖾𝗂𝗈. 𝖮𝗋𝖺, 𝗎𝗆 𝖼𝖺𝗌𝖺𝗅 𝖾𝗆 𝗊𝗎𝖾 𝖺 𝗆𝗎𝗅𝗁𝖾𝗋 𝖾𝗌𝗍𝖾𝗃𝖺 𝗉𝖾𝗋𝗍𝗈 𝖽𝗈𝗌 𝟥𝟩 𝖺𝗇𝗈𝗌 𝖽𝖾 𝗂𝖽𝖺𝖽𝖾 𝖾 𝗉𝗋𝖾𝗍𝖾𝗇𝖽𝖺 𝗂𝗇𝗂𝖼𝗂𝖺𝗋 𝗈 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈 𝖽𝖾 𝗉𝗋𝗈𝖼𝗋𝗂𝖺𝖼̧𝖺̃𝗈 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝖾 𝖺𝗌𝗌𝗂𝗌𝗍𝗂𝖽𝖺, 𝗌𝖺𝖻𝖾 𝖽𝖾 𝖺𝗇𝗍𝖾𝗆𝖺̃𝗈 𝗊𝗎𝖾 𝖺 𝗏𝗂𝖺𝖻𝗂𝗅𝗂𝖽𝖺𝖽𝖾 𝖽𝖾 𝗈 𝖼𝗈𝗇𝗌𝖾𝗀𝗎𝗂𝗋 𝖾𝖿𝖾𝖼𝗍𝗎𝖺𝗋 𝖺𝗇𝗍𝖾𝗌 𝖽𝗈𝗌 𝟦𝟢 𝖺𝗇𝗈𝗌 𝖾́ 𝖻𝖺𝗂𝗑𝖺 - 𝗇𝖺̃𝗈 𝖾𝗌𝗊𝗎𝖾𝖼𝖾𝗇𝖽𝗈 𝗊𝗎𝖾, 𝗆𝖾𝗌𝗆𝗈 𝗊𝗎𝖾 𝗈 𝖼𝗈𝗇𝗌𝗂𝗀𝖺 𝗋𝖾𝖺𝗅𝗂𝗓𝖺𝗋 𝖾𝗆 𝗍𝖾𝗆𝗉𝗈 𝗎́𝗍𝗂𝗅, 𝗈 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈 𝗍𝖾𝗆 𝖾𝗅𝖾𝗏𝖺𝖽𝖺𝗌 𝗍𝖺𝗑𝖺𝗌 𝖽𝖾 𝗂𝗇𝗌𝗎𝖼𝖾𝗌𝗌𝗈 𝖺𝗌𝗌𝗈𝖼𝗂𝖺𝖽𝖺𝗌.
𝖲𝖾𝗆 𝗀𝗋𝖺𝗇𝖽𝖾 𝗌𝗎𝗋𝗉𝗋𝖾𝗌𝖺, 𝖺𝗍𝖾𝗇𝖽𝖾𝗇𝖽𝗈 𝖺̀ 𝖽𝗂𝗆𝗂𝗇𝗎𝗂𝖼̧𝖺̃𝗈 𝖾𝗑𝗉𝗈𝗇𝖾𝗇𝖼𝗂𝖺𝗅 𝖽𝖺 𝗊𝗎𝖺𝗅𝗂𝖽𝖺𝖽𝖾 𝖽𝗈𝗌 𝗌𝖾𝗋𝗏𝗂𝖼̧𝗈𝗌 𝗉𝗎́𝖻𝗅𝗂𝖼𝗈𝗌 𝖾𝗆 𝖯𝗈𝗋𝗍𝗎𝗀𝖺𝗅, 𝖺𝗌 𝖿𝖺𝗆𝗂́𝗅𝗂𝖺𝗌 𝖼𝗈𝗆 𝗆𝖺𝗂𝗌 𝗋𝖾𝖼𝗎𝗋𝗌𝗈𝗌 𝗍𝖾𝗇𝖽𝖾𝗆 𝖺 𝗉𝗋𝗈𝖼𝗎𝗋𝖺𝗋 𝖾𝗌𝗍𝖾 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈 𝗇𝗈 𝗌𝖾𝖼𝗍𝗈𝗋 𝗉𝗋𝗂𝗏𝖺𝖽𝗈. 𝖤𝗌𝗍𝖺 𝖾𝗌𝖼𝗈𝗅𝗁𝖺 (𝗉𝖺𝗋𝖺 𝗈𝗌 𝗊𝗎𝖾 𝖺 𝗉𝗈𝖽𝖾𝗆 𝖿𝖺𝗓𝖾𝗋) 𝗇𝖺̃𝗈 𝖺𝖽𝗏𝖾́𝗆 𝖾𝗑𝖼𝗅𝗎𝗌𝗂𝗏𝖺𝗆𝖾𝗇𝗍𝖾 𝖽𝖺 𝗆𝖺𝗂𝗈𝗋 𝖼𝖾𝗅𝖾𝗋𝗂𝖽𝖺𝖽𝖾 𝗇𝖺 𝗋𝖾𝗌𝗉𝗈𝗌𝗍𝖺 𝗈𝖿𝖾𝗋𝖾𝖼𝗂𝖽𝖺 𝗉𝖾𝗅𝗈𝗌 𝗉𝗋𝖾𝗌𝗍𝖺𝖽𝗈𝗋𝖾𝗌 𝗉𝗋𝗂𝗏𝖺𝖽𝗈𝗌, 𝗆𝖺𝗌, 𝖾𝗆 𝗉𝖺𝗋𝗍𝗂𝖼𝗎𝗅𝖺𝗋, 𝖽𝖾𝗏𝗂𝖽𝗈 𝖺̀ 𝗂𝖽𝖺𝖽𝖾 𝗆𝖺́𝗑𝗂𝗆𝖺 𝖼𝗈𝗆 𝗊𝗎𝖾 𝖺 𝗆𝗎𝗅𝗁𝖾𝗋 𝗉𝗈𝖽𝖾 𝖺𝖼𝖾𝖽𝖾𝗋 𝖺𝗈𝗌 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈𝗌 𝗌𝖾𝗋 𝖽𝖾 𝟧𝟢 𝖺𝗇𝗈𝗌 - 𝖾𝗆 𝖼𝗈𝗆𝗉𝖺𝗋𝖺𝖼̧𝖺̃𝗈 𝖼𝗈𝗆 𝗈𝗌 𝟦𝟢 𝖺𝗇𝗈𝗌 𝗇𝗈 𝗌𝖾𝖼𝗍𝗈𝗋 𝗉𝗎́𝖻𝗅𝗂𝖼𝗈. 𝖯𝖺𝗋𝖺𝗅𝖾𝗅𝖺𝗆𝖾𝗇𝗍𝖾, 𝖺 𝗈𝖿𝖾𝗋𝗍𝖺 𝖾 𝖼𝗈𝖻𝖾𝗋𝗍𝗎𝗋𝖺 𝗍𝖾𝗋𝗋𝗂𝗍𝗈𝗋𝗂𝖺𝗅 𝗇𝗈 𝗉𝗋𝗂𝗏𝖺𝖽𝗈 𝖾́ 𝗅𝖺𝗋𝗀𝖺𝗆𝖾𝗇𝗍𝖾 𝗌𝗎𝗉𝖾𝗋𝗂𝗈𝗋, 𝗈 𝗊𝗎𝖾 𝗉𝗈𝗌𝗌𝗂𝖻𝗂𝗅𝗂𝗍𝖺 𝗊𝗎𝖾 𝗆𝖺𝗂𝗌 𝗍𝖾𝗇𝗍𝖺𝗍𝗂𝗏𝖺𝗌 𝖽𝖾𝗌𝗍𝖾 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈 𝗉𝗈𝗌𝗌𝖺𝗆 𝗌𝖾𝗋 𝗋𝖾𝖺𝗅𝗂𝗓𝖺𝖽𝖺𝗌 𝗌𝖾𝗆 𝖼𝖺𝗎𝗌𝖺𝗋 𝗍𝗋𝖺𝗇𝗌𝗍𝗈𝗋𝗇𝗈𝗌 𝗌𝗂𝗀𝗇𝗂𝖿𝗂𝖼𝖺𝗍𝗂𝗏𝗈𝗌 𝗇𝗈 𝖽𝗂𝖺-𝖺-𝖽𝗂𝖺 𝖽𝗈𝗌 𝗉𝖺𝖼𝗂𝖾𝗇𝗍𝖾𝗌.
𝖲𝖾𝗀𝗎𝗇𝖽𝗈 𝗈 𝖢𝗈𝗇𝗌𝖾𝗅𝗁𝗈 𝖭𝖺𝖼𝗂𝗈𝗇𝖺𝗅 𝖽𝖾 𝖯𝗋𝗈𝖼𝗋𝗂𝖺𝖼̧𝖺̃𝗈 𝖬𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝖾 𝖠𝗌𝗌𝗂𝗌𝗍𝗂𝖽𝖺, 𝗈𝗌 𝗇𝖺𝗌𝖼𝗂𝗆𝖾𝗇𝗍𝗈𝗌 𝗋𝖾𝗌𝗎𝗅𝗍𝖺𝗇𝗍𝖾𝗌 𝖽𝖾 𝗉𝗋𝗈𝖼𝗋𝗂𝖺𝖼̧𝖺̃𝗈 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝖾 𝖺𝗌𝗌𝗂𝗌𝗍𝗂𝖽𝖺 𝗋𝖾𝗉𝗋𝖾𝗌𝖾𝗇𝗍𝖺𝗆 𝗁𝗈𝗃𝖾 𝗆𝖺𝗂𝗌 𝖽𝖾 𝟦% 𝖽𝖺 𝗇𝖺𝗍𝖺𝗅𝗂𝖽𝖺𝖽𝖾 𝖺𝖻𝗌𝗈𝗅𝗎𝗍𝖺 𝗇𝗈 𝗇𝗈𝗌𝗌𝗈 𝗉𝖺𝗂́𝗌 - 𝗈 𝖾𝗊𝗎𝗂𝗏𝖺𝗅𝖾𝗇𝗍𝖾 𝖺 𝖼𝖾𝗋𝖼𝖺 𝖽𝖾 𝟥𝟧𝟢𝟢 𝗇𝖺𝗌𝖼𝗂𝗆𝖾𝗇𝗍𝗈𝗌 𝗉𝗈𝗋 𝖺𝗇𝗈. 𝖠𝖼𝗍𝗎𝖺𝗅𝗆𝖾𝗇𝗍𝖾 𝗈𝗌 𝖼𝖾𝗇𝗍𝗋𝗈𝗌 𝗉𝗎́𝖻𝗅𝗂𝖼𝗈𝗌 𝖽𝖾 𝗉𝗋𝗈𝖼𝗋𝗂𝖺𝖼̧𝖺̃𝗈 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝖾 𝖺𝗌𝗌𝗂𝗌𝗍𝗂𝖽𝖺 𝗌𝖺̃𝗈 𝗋𝖾𝗌𝗉𝗈𝗇𝗌𝖺́𝗏𝖾𝗂𝗌 𝗉𝗈𝗋 𝗆𝖾𝗇𝗈𝗌 𝖽𝖾 𝗎𝗆 𝗍𝖾𝗋𝖼̧𝗈 𝖽𝖺 𝗍𝗈𝗍𝖺𝗅𝗂𝖽𝖺𝖽𝖾 𝖽𝗈𝗌 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈𝗌 𝖾𝖿𝖾𝖼𝗍𝗎𝖺𝖽𝗈𝗌, 𝗈 𝗊𝗎𝖾 𝗋𝖾𝗌𝗎𝗅𝗍𝖺, 𝗇𝖺𝗍𝗎𝗋𝖺𝗅𝗆𝖾𝗇𝗍𝖾, 𝖽𝖺 𝗉𝗋𝗈𝗀𝗋𝖾𝗌𝗌𝗂𝗏𝖺 𝗋𝖾𝗌𝗂𝗀𝗇𝖺𝖼̧𝖺̃𝗈 𝖽𝗈𝗌 𝗉𝖺𝖼𝗂𝖾𝗇𝗍𝖾𝗌 𝖼𝗈𝗆 𝗈 𝖲𝖭𝖲 𝖾 𝖺 𝗋𝖾𝗌𝗉𝖾𝖼𝗍𝗂𝗏𝖺 𝖾𝗌𝖼𝗈𝗅𝗁𝖺 𝗉𝖾𝗅𝗈 𝗌𝖾𝖼𝗍𝗈𝗋 𝗉𝗋𝗂𝗏𝖺𝖽𝗈.
𝖭𝗈𝗌 𝗎́𝗅𝗍𝗂𝗆𝗈𝗌 𝖽𝗂𝖺𝗌 𝖿𝗈𝗂 𝗇𝗈𝗍𝗂𝖼𝗂𝖺𝖽𝗈 𝗊𝗎𝖾 𝗆𝗂𝗅𝗁𝖺𝗋𝖾𝗌 𝖽𝖾 𝗀𝖺𝗆𝖾𝗍𝖺𝗌 𝖾 𝖾𝗆𝖻𝗋𝗂𝗈̃𝖾𝗌 𝖺𝗋𝗆𝖺𝗓𝖾𝗇𝖺𝖽𝗈𝗌 𝗇𝗈𝗌 𝖼𝖾𝗇𝗍𝗋𝗈𝗌 𝖽𝖾 𝗉𝗋𝗈𝖼𝗋𝗂𝖺𝖼̧𝖺̃𝗈 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝖾 𝖺𝗌𝗌𝗂𝗌𝗍𝗂𝖽𝖺 𝗌𝖾𝗋𝗂𝖺𝗆 𝖽𝖾𝗌𝖼𝗈𝗇𝗀𝖾𝗅𝖺𝖽𝗈𝗌 𝖾𝗆 𝖠𝗀𝗈𝗌𝗍𝗈, 𝗍𝗈𝗋𝗇𝖺𝗇𝖽𝗈-𝗌𝖾, 𝗉𝗈𝗋𝗍𝖺𝗇𝗍𝗈, 𝗂𝗇𝗎𝗍𝗂𝗅𝗂𝗓𝖺́𝗏𝖾𝗂𝗌 - 𝗂𝗌𝗍𝗈 𝖺𝗉𝖾𝗌𝖺𝗋 𝖽𝖺𝗌 𝗉𝖾𝗌𝗌𝗈𝖺𝗌 𝖾𝗆 𝗅𝗂𝗌𝗍𝖺 𝖽𝖾 𝖾𝗌𝗉𝖾𝗋𝖺 𝖺𝗌𝖼𝖾𝗇𝖽𝖾𝗋𝖾𝗆 𝖺 𝗏𝖺́𝗋𝗂𝖺𝗌 𝖼𝖾𝗇𝗍𝖾𝗇𝖺𝗌.
𝖤𝗌𝗍𝖺 𝖽𝖾𝖼𝗂𝗌𝖺̃𝗈 𝖽𝖾𝖼𝗈𝗋𝗋𝖾 𝖽𝖾 𝗎𝗆𝖺 𝖺𝗅𝗍𝖾𝗋𝖺𝖼̧𝖺̃𝗈 𝗅𝖾𝗀𝗂𝗌𝗅𝖺𝗍𝗂𝗏𝖺 𝖽𝖺𝗍𝖺𝖽𝖺 𝖽𝖾 𝟤𝟢𝟣𝟫 𝗊𝗎𝖾 𝗂𝗇𝗍𝗋𝗈𝖽𝗎𝗓𝗂𝗎 𝗈 𝖿𝗂𝗆 𝖽𝗈 𝖺𝗇𝗈𝗇𝗂𝗆𝖺𝗍𝗈 𝗉𝖺𝗋𝖺 𝖺 𝖽𝗈𝖺𝖼̧𝖺̃𝗈 𝖽𝖾 𝗀𝖺𝗆𝖾𝗍𝖺𝗌 𝖾 𝖾𝗆𝖻𝗋𝗂𝗈̃𝖾𝗌 𝖾 𝗉𝗋𝖾𝗏𝗂𝖺 𝗎𝗆 𝗉𝖾𝗋𝗂́𝗈𝖽𝗈 𝖽𝖾 𝗍𝗋𝖺𝗇𝗌𝗂𝖼̧𝖺̃𝗈 𝖽𝗎𝗋𝖺𝗇𝗍𝖾 𝗈 𝗊𝗎𝖺𝗅 𝗈 𝗆𝖺𝗍𝖾𝗋𝗂𝖺𝗅 𝗀𝖾𝗇𝖾́𝗍𝗂𝖼𝗈 𝗉𝗈𝖽𝖾𝗋𝗂𝖺 𝖼𝗈𝗇𝗍𝗂𝗇𝗎𝖺𝗋 𝖺 𝗌𝖾𝗋 𝗎𝗍𝗂𝗅𝗂𝗓𝖺𝖽𝗈 𝗉𝖾𝗅𝗈𝗌 𝖼𝖾𝗇𝗍𝗋𝗈𝗌 𝖽𝖾 𝗉𝗋𝗈𝖼𝗋𝗂𝖺𝖼̧𝖺̃𝗈 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝖾 𝖺𝗌𝗌𝗂𝗌𝗍𝗂𝖽𝖺. 𝖢𝗈𝗇𝗍𝗎𝖽𝗈, 𝖾𝗌𝗌𝖾 𝗉𝖾𝗋𝗂́𝗈𝖽𝗈 𝖽𝖾 𝗍𝗋𝖺𝗇𝗌𝗂𝖼̧𝖺̃𝗈 𝗍𝖾𝗋𝗆𝗂𝗇𝖺, 𝗉𝗋𝖾𝖼𝗂𝗌𝖺𝗆𝖾𝗇𝗍𝖾, 𝗇𝖾𝗌𝗍𝖾 𝗆𝖾̂𝗌 𝖽𝖾 𝖠𝗀𝗈𝗌𝗍𝗈.
𝖤𝗌𝗍𝖺 𝖺𝗅𝗍𝖾𝗋𝖺𝖼̧𝖺̃𝗈 𝗅𝖾𝗀𝗂𝗌𝗅𝖺𝗍𝗂𝗏𝖺 𝗇𝖺̃𝗈 𝖾́ 𝖾𝗑𝗉𝗅𝗂́𝖼𝗂𝗍𝖺 𝗊𝗎𝖺𝗇𝗍𝗈 𝖺̀ 𝗈𝖻𝗋𝗂𝗀𝖺𝗍𝗈𝗋𝗂𝖾𝖽𝖺𝖽𝖾 𝖽𝖺 𝖽𝖾𝗌𝗍𝗋𝗎𝗂𝖼̧𝖺̃𝗈 𝖽𝗈 𝗆𝖺𝗍𝖾𝗋𝗂𝖺𝗅 𝗀𝖾𝗇𝖾́𝗍𝗂𝖼𝗈 𝖾 𝗉𝗋𝖾𝗏𝖾̂-𝗌𝖾 𝗊𝗎𝖾 𝖼𝖺𝖽𝖺 𝖼𝖾𝗇𝗍𝗋𝗈 𝖽𝖾 𝗉𝗋𝗈𝖼𝗋𝗂𝖺𝖼̧𝖺̃𝗈 𝗆𝖾𝖽𝗂𝖼𝖺𝗆𝖾𝗇𝗍𝖾 𝖺𝗌𝗌𝗂𝗌𝗍𝗂𝖽𝖺 𝗉𝗈𝗌𝗌𝖺 𝗍𝗈𝗆𝖺𝗋 𝗎𝗆𝖺 𝖽𝖾𝖼𝗂𝗌𝖺̃𝗈 𝗋𝖾𝗅𝖺𝗍𝗂𝗏𝖺𝗆𝖾𝗇𝗍𝖾 𝖺𝗈 𝗆𝖺𝗍𝖾𝗋𝗂𝖺𝗅 𝖺𝗋𝗆𝖺𝗓𝖾𝗇𝖺𝖽𝗈 𝖺𝗇𝗍𝖾𝗌 𝖽𝖺 𝖺𝗅𝗍𝖾𝗋𝖺𝖼̧𝖺̃𝗈 𝖽𝖺 𝗅𝖾𝗂. 𝖠𝗍𝖾𝗇𝖽𝖾𝗇𝖽𝗈 𝖺̀ 𝗂𝗆𝗉𝗈𝗋𝗍𝖺̂𝗇𝖼𝗂𝖺 𝗊𝗎𝖾 𝗍𝖾𝗆 𝗉𝖺𝗋𝖺 𝖺 𝗇𝖺𝗍𝖺𝗅𝗂𝖽𝖺𝖽𝖾 𝗉𝗈𝗋𝗍𝗎𝗀𝗎𝖾𝗌𝖺, 𝗉𝗈𝖽𝖾𝗋𝖺́ 𝖾𝗌𝗉𝖾𝖼𝗎𝗅𝖺𝗋-𝗌𝖾 𝗊𝗎𝖾 𝖺 𝗆𝖺𝗂𝗈𝗋𝗂𝖺 𝖽𝖺𝗌 𝖽𝗂𝗋𝖾𝖼𝖼̧𝗈̃𝖾𝗌 𝗈𝗉𝗍𝖾 𝗉𝖾𝗅𝖺 𝗌𝗎𝖺 𝗉𝗋𝖾𝗌𝖾𝗋𝗏𝖺𝖼̧𝖺̃𝗈 𝖾𝗆 𝖽𝖾𝗍𝗋𝗂𝗆𝖾𝗇𝗍𝗈 𝖽𝖺 𝗌𝗎𝖺 𝖽𝖾𝗌𝗍𝗋𝗎𝗂𝖼̧𝖺̃𝗈.
𝖲𝖾 𝗈 𝗆𝖺𝗍𝖾𝗋𝗂𝖺𝗅 𝗀𝖾𝗇𝖾́𝗍𝗂𝖼𝗈 𝗇𝖾𝖼𝖾𝗌𝗌𝖺́𝗋𝗂𝗈 𝗉𝖺𝗋𝖺 𝖾𝗌𝗍𝖾 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈 𝖿𝗈𝗋 𝖾𝖿𝖾𝖼𝗍𝗂𝗏𝖺𝗆𝖾𝗇𝗍𝖾 𝗂𝗇𝗎𝗍𝗂𝗅𝗂𝗓𝖺𝖽𝗈 𝗊𝗎𝖺𝗇𝖽𝗈 𝖾𝗌𝗍𝖾 𝖾́, 𝗃𝖺́ 𝗉𝗈𝗋 𝗌𝗂, 𝖾𝗑𝗍𝗋𝖾𝗆𝖺𝗆𝖾𝗇𝗍𝖾 𝖻𝗎𝗋𝗈𝖼𝗋𝖺́𝗍𝗂𝖼𝗈, 𝖽𝖾𝗆𝗈𝗋𝖺𝖽𝗈 𝖾 𝖽𝖾𝗉𝖾𝗇𝖽𝖾𝗇𝗍𝖾 𝖽𝖾 𝖽𝗈𝖺𝖼̧𝗈̃𝖾𝗌 - 𝗊𝗎𝖾 𝗍𝖾̂𝗆 𝖽𝗂𝗆𝗂𝗇𝗎𝗂́𝖽𝗈 𝗌𝗎𝖻𝗌𝗍𝖺𝗇𝖼𝗂𝖺𝗅𝗆𝖾𝗇𝗍𝖾 𝖽𝖾𝗌𝖽𝖾 𝗈 𝖿𝗂𝗆 𝖽𝗈 𝖺𝗇𝗈𝗇𝗂𝗆𝖺𝗍𝗈 -, 𝖾𝗇𝗍𝖺̃𝗈 𝖼𝗋𝗂𝖺𝗋-𝗌𝖾-𝖺̃𝗈 𝖼𝖺𝖽𝖺 𝗏𝖾𝗓 𝗆𝖺𝗂𝗌 𝗈𝖻𝗌𝗍𝖺́𝖼𝗎𝗅𝗈𝗌 𝗉𝖺𝗋𝖺 𝗊𝗎𝖾 𝗈𝗌 𝗊𝗎𝖾 𝗇𝖾𝖼𝖾𝗌𝗌𝗂𝗍𝖺𝗆 𝖽𝖾 𝗋𝖾𝖼𝗈𝗋𝗋𝖾𝗋 𝖺 𝖾𝗌𝗍𝖾𝗌 𝗍𝗋𝖺𝗍𝖺𝗆𝖾𝗇𝗍𝗈𝗌 𝖼𝗈𝗇𝗌𝗂𝗀𝖺𝗆, 𝖾𝖿𝖾𝖼𝗍𝗂𝗏𝖺𝗆𝖾𝗇𝗍𝖾, 𝖼𝗈𝗇𝖼𝗋𝖾𝗍𝗂𝗓𝖺𝗋 𝗈 𝗌𝖾𝗎 𝖽𝖾𝗌𝖾𝗃𝗈 𝖽𝖾 𝗍𝖾𝗋 𝖿𝗂𝗅𝗁𝗈𝗌.
* Vice presidente da Juventude Popular (Centrista não?)
IN "DIÁRIO DE NOTÍCIAS" 13/08/24
NR: É a primeira vez que editamos um artigo desta jovem autora e gostámos do modo como foi abordado tema tão delicado. Assalta-nos uma dúvida, não sabemos muito bem o que é um país desenvolvido, se é a Noruega país que tem grande consideração pelo ser humano e demonstra nas suas políticas, ou se é 'israel' também considerado país desenvolvido mas que neste conflito que ainda decorre, assassinou mais de treze mil crianças palestinas garantidamente não belicosas? Como o artigo de opinião trata de fazer e bem nascer crianças...
Sem comentários:
Enviar um comentário